• malignant
  • We have done a gene expression analysis of synovial sarcoma using a genome-wide cDNA microarray and found that synovial sarcoma shared its molecular signature with malignant peripheral nerve sheath tumor, of which the precursors were neural crest-derived cells, and also identified a set of genes commonly up-regulated in synovial sarcoma including the fibroblast growth factor 18 ( FGF18 ) gene ( 13 ). (aacrjournals.org)
  • diagnosis
  • Although the precise function and the mechanism of oncogenesis are not yet clearly shown, the high sensitivity and specificity of the SYT-SSX fusion gene in synovial sarcoma have proven to be useful for molecular diagnosis ( 8 ). (aacrjournals.org)
  • rare
  • The development of endometrial stromal sarcomas (ESSs) in foci of endometriosis is extremely rare, and few cases have been reported in the literature to date, particularly with regard to multiple extrauterine ESS. (pubmedcentralcanada.ca)
  • cell
  • Growth inhibitory effects of FGFR inhibitors on synovial sarcoma cell lines were investigated in vitro and in vivo . (aacrjournals.org)
  • Disruption of the FGF signaling pathway in synovial sarcoma by specific inhibitors of FGFR caused cell cycle arrest leading to significant growth inhibition both in vitro and in vivo . (aacrjournals.org)
  • treatment
  • Despite little progress in clinical treatment during the last 20 years, cytogenetic and molecular genetic analyses have greatly improved the understanding of this type of tumor, especially with the discovery of the reciprocal translocation t(18;X)(q11;p11) creating an SYT-SSX fusion gene as a synovial sarcoma-specific genetic alteration ( 5 , 6 ). (aacrjournals.org)